Clinical trials: Immune-Related Adverse Events
Steven-Johnson Syndrome, Toxic Epidermal Necrolysis
Severe Cutaneous Adverse Reactions in Thailand
The multicenter registry of patients with severe cutaneous adverse reactions among tertiary medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of in…
- Conditions
- Steven-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction With Eosinophilia and Systemic Symptoms, Acute Generalized Exanthematous Pustulosis
- Trial name
- ThaiSCAR (NCT02574988)
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Renal Cell Carcinoma
Axitinib Therapy Management Study
The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI
- Trial name
- NCT04555603
- Testing
- Inlyta, Bavencio, Keytruda
- Where
- United States
- Sponsor
- Pfizer
Immune Checkpoint Inhibitors, Lung Cancer
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the…
- Trial name
- NCT05288569
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Patient Reported Outcome Measures, Patient Safety
ePRO-based Model of Care to Manage and Monitoring Symptoms of Cancer Patients Treated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (IrAEs) throughout and beyond treatment duration. These IrAEs can be varied and difficult to predict, as they can involve almost any organ, regardless of…
- Trial name
- IePRO (NCT05530187)
- Testing
- Electronic Patient-reported Outcomes-based Model of Care
- Where
- 2 sites in Switzerland
- Volunteers
- 198 people
- Sponsor
- Manuela Eicher
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG
Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years.
- Trial name
- DETECT (NCT04892667)
- Testing
- Intervention
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Large B-Cell Lymphoma, Drug Toxicity
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subset of non-Hodgkin's lymphoma (NHL). Central nervous system (CNS) involvement in patients with NHL is a serious complication.
- Trial name
- NCT05022797
- Testing
- Glucarpidase 1000 UNT [Voraxaze]
- Where
- 2 sites in Spain
- Volunteers
- 3 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer